There is significant room for growth, and it is projected that by 2030, around 35% of diabetes patients in the United States will be using GLP-1 medications, considering that about 65% of T2D patients also have obesity issues
In other locations, people appear more willing to tolerate injections if they believe the treatment will deliver meaningful weight loss results
Computational approaches for clinical, genomic and proteomic markers of response to glucagon-like peptide-1 therapy in type-2 diabetes mellitus: An exploratory analysis with machine learning algorithms
Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85]
Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition.
However, most formularies cover both Wegovy and Zepbound, so rebates are currently not driving competition, but rather stifling innovative management strategies
